Gencyte Therapeutics
Gencyte Therapeutics is focused on developing next-generation Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy for precision cancer treatment. They aim to create a novel, less toxic approach that can treat a wider variety of cancers, including solid tumors, addressing the limitations of current CAR-T therapies.
Industries
biopharma
biotechnology
test-and-measurement
Nr. of Employees
small (1-50)
Gencyte Therapeutics
Products
Next-Generation CAR-T Immunotherapy
A novel approach to CAR-T cell therapy aimed at reducing toxicity and expanding treatment to a wider range of cancers, including solid tumors.
Next-Generation CAR-T Immunotherapy
A novel approach to CAR-T cell therapy aimed at reducing toxicity and expanding treatment to a wider range of cancers, including solid tumors.
Next-Generation CAR-T Immunotherapy
A novel approach to CAR-T cell therapy aimed at reducing toxicity and expanding treatment to a wider range of cancers, including solid tumors.
Next-Generation CAR-T Immunotherapy
A novel approach to CAR-T cell therapy aimed at reducing toxicity and expanding treatment to a wider range of cancers, including solid tumors.
Expertise Areas
- CAR-T immunotherapy development
- Precision oncology / personalized immunotherapies
- Solid tumor immunotherapy approaches
- Immunotherapy safety and toxicity mitigation
Key Technologies
- Chimeric antigen receptor T-cell (CAR-T) therapy
- Cellular immunotherapy
- Precision / personalized immunotherapy methods
- Preclinical immuno-oncology models